MS trial phase 2 enrollment complete - Tiziana CEO on the foralumab breakthrough

By Proactive Investors / May 22, 2026 / www.youtube.com / Article Link


Tiziana Life Sciences has completed enrollment in its Phase 2 trial of foralumab for secondary progressive multiple sclerosis.

Recent News

Market still expecting strong growth for major gold producers
July 27, 2026 / www.canadianminingreport.com

Newmont starts Q2/26 strong, growth expected for gold majors
July 27, 2026 / www.canadianminingreport.com

Gold not the consensus play anymore
July 20, 2026 / www.canadianminingreport.com

Gold stocks drop to lowest levels this year
July 20, 2026 / www.canadianminingreport.com

A rebalancing of gold's ratios versus major commodities
July 14, 2026 / www.canadianminingreport.com
See all >
Share to Youtube Share to Facebook Facebook Share to Linkedin Share to Twitter Twitter Share to Tiktok